387 related articles for article (PubMed ID: 10234582)
1. Monitoring alendronate therapy for osteoporosis.
Braga de Castro Machado A; Hannon R; Eastell R
J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
[TBL] [Abstract][Full Text] [Related]
2. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
3. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
[TBL] [Abstract][Full Text] [Related]
4. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
5. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
6. Biochemical markers as predictors of rates of bone loss after menopause.
Rogers A; Hannon RA; Eastell R
J Bone Miner Res; 2000 Jul; 15(7):1398-404. PubMed ID: 10893690
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
8. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
[TBL] [Abstract][Full Text] [Related]
9. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
10. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
11. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
12. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
Masaryk P; Stancíková M; Letkovská A; Rovenský J
Vnitr Lek; 2002 Oct; 48(10):943-7. PubMed ID: 16737141
[TBL] [Abstract][Full Text] [Related]
13. Relationship of bone turnover to bone density and fractures.
Melton LJ; Khosla S; Atkinson EJ; O'Fallon WM; Riggs BL
J Bone Miner Res; 1997 Jul; 12(7):1083-91. PubMed ID: 9200008
[TBL] [Abstract][Full Text] [Related]
14. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
15. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
Rizzoli R; Greenspan SL; Bone G; Schnitzer TJ; Watts NB; Adami S; Foldes AJ; Roux C; Levine MA; Uebelhart B; Santora AC; Kaur A; Peverly CA; Orloff JJ;
J Bone Miner Res; 2002 Nov; 17(11):1988-96. PubMed ID: 12412806
[TBL] [Abstract][Full Text] [Related]
16. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
Choi HJ; Im JA; Kim SH
Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
[TBL] [Abstract][Full Text] [Related]
17. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
18. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis.
Shaarawy M; Zaki S; Sheiba M; El-Minawi AM
Clin Lab; 2003; 49(11-12):625-36. PubMed ID: 14651333
[TBL] [Abstract][Full Text] [Related]
19. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Shin CS
Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
[TBL] [Abstract][Full Text] [Related]
20. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]